In about 15% of ALCL, ALK- patients JAK1 (G1097) mutations and/or STAT3 (Y640) mutations have been described and lead to increased oncogenic signalling and to Ruxolitinib resistance in the latter cases [6]. This evidence concerns the gene STAT3 and anaplastic large cell lymphoma.